Waterford biotech firm acquired by US company for €172m

ARTeSYN is expected to contribute up to $36 million in revenue in 2021 for Repligen

Last year, the company announced plans to create 50 jobs and invest €1 million in its manufacturing and cleanroom facilities in Waterford. Picture: Artesyn

Waterford-based ARTeSYN Biosolutions, which manufacturers single-use solutions for biopharma processing, has been acquired by US company Repligen for €172 million.

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, acquired the Waterford company in a $200 million deal comprising of approximately $130 million in cash and approximately $70 million in Repligen common stock.